The Digest’s 2025 Multi-Slide Guide to Novonesis
Novonesis highlights its successful combination of Novozymes and Chr. Hansen in 2024, achieving 8% organic sales growth and a 36.1% adjusted EBITDA margin. The company reached 80% of its cost synergy run-rate in the first year. For 2025, Novonesis expects 5-8% organic sales growth and a 37-38% adjusted EBITDA margin. Post-reporting, they announced the EUR 1.5 billion acquisition of dsm-firmenich’s Feed Enzyme Alliance, reinforcing their biosolutions leadership
